title: Expression kinetics of chicken β2-microglobulin and Class I MHC in vitro and in vivo during Marek's disease viral infections.
abstract: Marek's disease virus (MDV) is a highly cell-associated herpesvirus that causes a disease in chickens characterized by tumor formation and immunosuppression. The changes of major histocompatibility complex (MHC) expression in different MDV-infected cells are not completely understood. In this study, we investigated the expression of the Class I MHC and β2-microglobulin (β2m) genes in response to MDV infection at different time points by real-time PCR. In both in vitro and in vivo, the expression levels of Class I MHC and β2m genes were upregulated during early MDV infections in comparison to control cells; We also found that the expression of Class I MHC gene was downregulated in BudR (5-bromo-2'-deoxyuridine)-treated MSB1 cells at 48 h and MDV-infected chicken embryo fibroblast cells (CEF) at 120 and 168 h post infection (hpi); Furthermore, compared to control groups, Class I MHC and β2m expression levels were downregulated in peripheral blood lymphocytes (PBLC) from MDV-infected chickens at 14 and 28 days post infection (dpi); Interestingly, both Class I MHC and β2m gene expression levels increased again in PBLC from MDV RB1B-infected chickens at 35 dpi, in which MDV was in the latent or transformed infection stages. In addition, Class I MHC expression was clearly decreased in MDV-infected CEF at 120 hpi although β2m expression was significantly increased. These changes in Class I MHC and β2m gene expression might provide more insights into host-virus interaction.
authors.affiliation: Ministry of Education Key Lab for Avian Preventive Medicine, Yangzhou University, No.12 East Wenhui Road, Yangzhou, Jiangsu, 225009, People's Republic of China.
authors.forename: Chuan
authors.initials: C
authors.lastname: Yu
authors.forename: Qiu
authors.initials: Q
authors.lastname: Liu
authors.forename: Aijian
authors.initials: A
authors.lastname: Qin
authors.forename: Xuming
authors.initials: X
authors.lastname: Hu
authors.forename: Wencai
authors.initials: W
authors.lastname: Xu
authors.forename: Kun
authors.initials: K
authors.lastname: Qian
authors.forename: Hongxia
authors.initials: H
authors.lastname: Shao
authors.forename: Wenjie
authors.initials: W
authors.lastname: Jin
mesh_terms: D000818:Animals; D002460:Cell Line; D002645:Chickens / Q000276:immunology*; D020869:Gene Expression Profiling; D005786:Gene Expression Regulation / Q000276:immunology*; D008381:Herpesvirus 2, Gallid / Q000276:immunology*; D015395:Histocompatibility Antigens Class I / Q000235:genetics* / Q000276:immunology; D008380:Marek Disease / Q000276:immunology*; D001613:beta 2-Microglobulin / Q000235:genetics* / Q000276:immunology
chemical_list: D015395:Histocompatibility Antigens Class I; D001613:beta 2-Microglobulin
references.citation: Poult Sci. 2010 Oct;89(10):2123-9
references.pmid: 20852103
references.citation: Avian Pathol. 1995 Dec;24(4):597-609
references.pmid: 18645817
references.citation: Virology. 2008 Jan 20;370(2):323-32
references.pmid: 17949771
references.citation: Immunol Cell Biol. 2003 Jun;81(3):217-23
references.pmid: 12752686
references.citation: J Virol. 2012 Dec;86(23):12503-11
references.pmid: 22973043
references.citation: Mol Med Today. 1997 Mar;3(3):116-23
references.pmid: 9095486
references.citation: Virology. 2007 Mar 1;359(1):212-9
references.pmid: 17028059
references.citation: J Gen Virol. 1981 Mar;53(Pt 1):133-43
references.pmid: 6268738
references.citation: Clin Cancer Res. 2006 Dec 15;12(24):7294-305
references.pmid: 17189401
references.citation: Curr Top Microbiol Immunol. 2001;255:25-55
references.pmid: 11217426
references.citation: Viral Immunol. 2008 Jun;21(2):267-72
references.pmid: 18570592
references.citation: Virology. 1996 Aug 1;222(1):87-99
references.pmid: 8806490
references.citation: Virology. 2001 Mar 30;282(1):198-205
references.pmid: 11259202
references.citation: Viral Immunol. 2009 Oct;22(5):321-7
references.pmid: 19811089
references.citation: Poult Sci. 2010 Oct;89(10):2083-91
references.pmid: 20852098
references.citation: J Urol. 2007 Jul;178(1):10-1
references.pmid: 17574050
references.citation: J Infect Dis. 2001 Oct 15;184(8):947-54
references.pmid: 11574908
references.citation: J Urol. 2007 Jul;178(1):292-300
references.pmid: 17499801
references.citation: Nat Rev Microbiol. 2006 Apr;4(4):283-94
references.pmid: 16541136
references.citation: Vet Immunol Immunopathol. 1986 Jan;11(1):65-72
references.pmid: 2420060
references.citation: Comp Immunol Microbiol Infect Dis. 2003 May;26(3):189-98
references.pmid: 12581748
references.citation: EMBO J. 2002 Apr 2;21(7):1638-49
references.pmid: 11927548
references.citation: Cancer Res. 2006 Sep 15;66(18):9108-16
references.pmid: 16982753
references.citation: Cancer. 2010 May 1;116(9):2188-200
references.pmid: 20198709
references.citation: J Virol. 2000 Jun;74(11):5300-9
references.pmid: 10799607
references.citation: Tumori. 2010 Jan-Feb;96(1):117-21
references.pmid: 20437868
references.citation: Biochem Biophys Res Commun. 2011 Jun 17;409(4):792-8
references.pmid: 21621523
references.citation: Drug Discov Today. 2009 Jan;14(1-2):25-30
references.pmid: 19056512
references.citation: J Virol. 2012 Aug;86(15):8059-71
references.pmid: 22623773
references.citation: Crit Rev Immunol. 1992;12(1-2):47-79
references.pmid: 1358107
references.citation: Virus Res. 2010 Nov;153(2):250-7
references.pmid: 20723570
references.citation: J Immunol. 2005 Jan 1;174(1):6-19
references.pmid: 15622565
references.citation: Int J Immunopharmacol. 1987;9(4):459-68
references.pmid: 3114155
references.citation: Methods. 2001 Dec;25(4):402-8
references.pmid: 11846609
references.citation: Leuk Res. 2010 Sep;34(9):e248-9
references.pmid: 20392494